Patents by Inventor Craig C. Mello
Craig C. Mello has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7893036Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: GrantFiled: March 26, 2008Date of Patent: February 22, 2011Assignee: University of MassachusettsInventors: Phillip D. Zamore, Juanita McLachlan, Gyoergy Hutvagner, Alla Grishok, Craig C. Mello
-
Publication number: 20100234448Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: ApplicationFiled: March 19, 2010Publication date: September 16, 2010Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Phillip D. ZAMORE, Juanita MCLACHLAN, Gyorgy HUTVAGNER, Alla GRISHOK, Craig C. MELLO
-
Publication number: 20100233810Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: ApplicationFiled: March 23, 2010Publication date: September 16, 2010Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Phillip D. ZAMORE, Juanita MCLACHLAN, Gyorgy HUTVAGNER, Alla GRISHOK, Craig C. MELLO
-
Patent number: 7759463Abstract: Genes involved in double-stranded RNA interference (RNAi pathway genes) are identified and used to investigate the RNAi pathway. The genes and their products are also useful for modulating RNAi pathway activity.Type: GrantFiled: February 22, 2007Date of Patent: July 20, 2010Assignee: University of MassachusettsInventors: Craig C. Mello, Hiroaki Tabara, Andrew Fire, Alla Grishok
-
Patent number: 7691995Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: GrantFiled: July 12, 2002Date of Patent: April 6, 2010Assignee: University of MassachusettsInventors: Phillip D. Zamore, Juanita McLachlan, Gyorgy Hutvagner, Alla Grishok, Craig C. Mello
-
Patent number: 7622633Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: GrantFiled: October 30, 2002Date of Patent: November 24, 2009Assignee: Carnegie Institution of WashingtonInventors: Andrew Fire, Stephen Kostas, Mary Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig C. Mello
-
Patent number: 7560438Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: GrantFiled: October 30, 2002Date of Patent: July 14, 2009Assignees: The Carnegie Institution of Washington, The University of MassachusettsInventors: Andrew Fire, Stephen Kostas, Mary Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig C. Mello
-
Patent number: 7538095Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: GrantFiled: October 30, 2002Date of Patent: May 26, 2009Assignees: The Carnegie Institution of Washington, The University of MassachusettsInventors: Andrew Fire, Stephen Kostas, Mary Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig C. Mello
-
Publication number: 20080305543Abstract: Genes involved in double-stranded RNA interference (RNAi pathway genes) are identified and used to investigate the RNAi pathway. The genes and their products are also useful for modulating RNAi pathway activity.Type: ApplicationFiled: February 22, 2007Publication date: December 11, 2008Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Craig C. Mello, Andrew Fire, Hiroaki Tabara, Alla Grishok
-
Publication number: 20080248576Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: ApplicationFiled: September 28, 2007Publication date: October 9, 2008Applicants: Carnegie Institution of Washington, the, University of Massachusetts, theInventors: Andrew Fire, Stephen Kostas, Mary Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig C. Mello
-
Publication number: 20080200420Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: ApplicationFiled: March 26, 2008Publication date: August 21, 2008Inventors: Phillip D. Zamore, Juanita McLachlan, Gyorgy Hutvagner, Alla Grishok, Craig C. Mello
-
Patent number: 7282564Abstract: Genes involved in double-stranded RNA interference (RNAi pathway genes) are identified and used to investigate the RNAi pathway. The genes and their products are also useful for modulating RNAi pathway activity.Type: GrantFiled: August 20, 2003Date of Patent: October 16, 2007Assignees: University of Massachusetts, Carnegie Institute of WashingtonInventors: Craig C. Mello, Andrew Fire, Hiroaki Tabara, Alla Grishok
-
Publication number: 20040265839Abstract: Genes involved in double-stranded RNA interference (RNAi pathway genes) are identified and used to investigate the RNAi pathway. The genes and their products are also useful for modulating RNAi pathway activity.Type: ApplicationFiled: August 20, 2003Publication date: December 30, 2004Applicant: UNIVERSITY OF MASSACHUSETTS MEDICALInventors: Craig C. Mello, Andrew Fire, Hiroaki Tabara, Alla Grishok
-
Publication number: 20030114409Abstract: The present invention features compositions and methods to induce or enhance RNAi in cells, systems, and organisms using molecules that mediate RNAi in invertebrates such as C. elegans.Type: ApplicationFiled: November 15, 2002Publication date: June 19, 2003Inventors: Craig C. Mello, Chun-Chieh Chen, Darryl Conte
-
Publication number: 20030056235Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: ApplicationFiled: October 30, 2002Publication date: March 20, 2003Applicant: THE CARNEGIE INSTITUTION OF WASHINGTONInventors: Andrew Fire, Stephen Kostas, Mary Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig C. Mello
-
Publication number: 20030055020Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: ApplicationFiled: October 30, 2002Publication date: March 20, 2003Applicant: The Carnegie Institution of WashingtonInventors: Andrew Fire, Stephen Kostas, Mary Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig C. Mello
-
Publication number: 20030051263Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: ApplicationFiled: October 30, 2002Publication date: March 13, 2003Applicant: The Carnegie Institution of WashingtonInventors: Andrew Fire, Stephen Kostas, Mary Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig C. Mello
-
Patent number: 6506559Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: GrantFiled: December 18, 1998Date of Patent: January 14, 2003Assignee: Carnegie Institute of WashingtonInventors: Andrew Fire, Stephen Kostas, Mary Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig C. Mello